# A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

> **NCT04929249** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 450 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Inclisiran

## Key facts

- **NCT ID:** NCT04929249
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-25
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04929249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04929249, "A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04929249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*